NCT03804164

Brief Summary

This pilot trial studies how well a psycho-educational program called Emerging from the Haze works in helping patients with blood and lymph cancer. Sometimes, patients who have undergone treatment for cancer experience thinking or memory problems that make work, school, or everyday life activities, such as grocery shopping, difficult. The Emerging from the Haze program may provide resources to help deal with these types of challenges in patients with blood and lymph cancer.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 15, 2019

Completed
1.1 years until next milestone

Study Start

First participant enrolled

February 10, 2020

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 10, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 10, 2020

Completed
Last Updated

December 17, 2020

Status Verified

December 1, 2020

Enrollment Period

Same day

First QC Date

January 11, 2019

Last Update Submit

December 15, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Enrollment of eligible participants (accrual)

    Feasibility will be assessed through enrollment of \>= 60% of eligible participants (accrual) and completion of at least 5 out of 6 sessions for \>= 80% of participants (adherence/engagement).

    Up to 30 days post the end of the six-week program

  • Completion of sessions (adherence/engagement)

    Feasibility will be assessed through enrollment of \>= 60% of eligible participants (accrual) and completion of at least 5 out of 6 sessions for \>= 80% of participants (adherence/engagement).

    Up to 30 days post the end of the six-week program

Secondary Outcomes (5)

  • Change in Functional Assessment of Cancer Therapy-Cognition scores

    Baseline up to 30 days post the end of the six-week program

  • Change in Patient Reported Outcomes Measurement Information System (PROMIS) scores

    Baseline up to 30 days post the end of the six-week program

  • Change in Global Self-Report of Cognition scores

    Baseline up to 30 days post the end of the six-week program

  • Change in PROMIS-29 items (29) scores

    Baseline up to 30 days post the end of the six-week program

  • Satisfaction Survey scores

    Up to 30 days post the end of the six-week program

Study Arms (1)

Supportive Care (psycho-educational sessions)

EXPERIMENTAL

Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.

Other: Educational InterventionOther: Quality-of-Life AssessmentOther: Survey Administration

Interventions

Attend Emerging from the Haze psychoeducational sessions

Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Supportive Care (psycho-educational sessions)

Ancillary studies

Also known as: Quality of Life Assessment
Supportive Care (psycho-educational sessions)

Ancillary studies

Supportive Care (psycho-educational sessions)

Eligibility Criteria

Age18 Years - 39 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • A diagnosis of a hematological malignancy.
  • Having received chemotherapy with or without radiation therapy.
  • Physician approval.
  • Functional Assessment of Cancer Therapy-Cognition (FACT-COG) score \< 59 on the perceived cognitive impairments (PCI) subscale.
  • Eligible after 2 months (60 +/- 5 days) of completing all their active cancer treatment with the exception of patients that are post-transplant.
  • Subjective complaint of cognitive concerns at time of enrollment.
  • Must be able to understand and communicate proficiently in English.
  • Ability to understand and the willingness to sign a written informed consent.
  • Agree to complete study surveys.

You may not qualify if:

  • Patients who have significant personality disorders or unstable psychiatric disorders as assessed by the interviewing clinician.
  • Patients with known brain metastases, history of brain metastases or radiation to the brain.
  • Patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction.
  • Non-English speaking patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

City of Hope Medical Center

Duarte, California, 91010, United States

Location

MeSH Terms

Conditions

Hematologic Neoplasms

Interventions

Early Intervention, EducationalEducational StatusMethods

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Child Health ServicesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and ServicesPreventive Health ServicesSocioeconomic FactorsPopulation CharacteristicsInvestigative Techniques

Study Officials

  • Natalie Kelly, PhD

    City of Hope Medical Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2019

First Posted

January 15, 2019

Study Start

February 10, 2020

Primary Completion

February 10, 2020

Study Completion

February 10, 2020

Last Updated

December 17, 2020

Record last verified: 2020-12

Locations